NN Investment Partners Holdings N.V. Has $52.68 Million Holdings in Bristol-Myers Squibb (NYSE:BMY)

NN Investment Partners Holdings N.V. lifted its holdings in Bristol-Myers Squibb (NYSE:BMY) by 9.5% during the 1st quarter, according to its most recent disclosure with the SEC. The institutional investor owned 834,529 shares of the biopharmaceutical company’s stock after acquiring an additional 72,584 shares during the period. NN Investment Partners Holdings N.V.’s holdings in Bristol-Myers Squibb were worth $52,683,000 as of its most recent filing with the SEC.

Other hedge funds have also added to or reduced their stakes in the company. B. Metzler seel. Sohn & Co. Holding AG acquired a new stake in Bristol-Myers Squibb during the fourth quarter worth about $126,946,000. State of Michigan Retirement System grew its stake in Bristol-Myers Squibb by 285.8% during the fourth quarter. State of Michigan Retirement System now owns 2,291,043 shares of the biopharmaceutical company’s stock worth $142,113,000 after buying an additional 1,697,200 shares in the last quarter. Principal Financial Group Inc. grew its stake in Bristol-Myers Squibb by 27.4% during the fourth quarter. Principal Financial Group Inc. now owns 4,684,936 shares of the biopharmaceutical company’s stock worth $290,607,000 after buying an additional 1,006,280 shares in the last quarter. State of Tennessee Treasury Department grew its stake in Bristol-Myers Squibb by 139.5% during the fourth quarter. State of Tennessee Treasury Department now owns 1,508,204 shares of the biopharmaceutical company’s stock worth $93,555,000 after buying an additional 878,388 shares in the last quarter. Finally, Rothschild & Co. Asset Management US Inc. grew its stake in Bristol-Myers Squibb by 112.0% during the fourth quarter. Rothschild & Co. Asset Management US Inc. now owns 1,314,523 shares of the biopharmaceutical company’s stock worth $81,540,000 after buying an additional 694,428 shares in the last quarter. Institutional investors and hedge funds own 72.41% of the company’s stock.

Shares of NYSE:BMY traded up $0.28 during mid-day trading on Tuesday, hitting $63.76. The company had a trading volume of 258,819 shares, compared to its average volume of 12,447,705. The firm has a fifty day moving average price of $63.60 and a 200 day moving average price of $63.04. The company has a market capitalization of $142.44 billion, a PE ratio of -577.04, a price-to-earnings-growth ratio of 1.00 and a beta of 0.67. The company has a debt-to-equity ratio of 0.82, a current ratio of 1.67 and a quick ratio of 1.58. Bristol-Myers Squibb has a one year low of $54.07 and a one year high of $67.16.

Bristol-Myers Squibb (NYSE:BMY) last released its quarterly earnings data on Wednesday, April 28th. The biopharmaceutical company reported $1.74 earnings per share for the quarter, missing the consensus estimate of $1.82 by ($0.08). The company had revenue of $11.07 billion during the quarter, compared to the consensus estimate of $11.19 billion. Bristol-Myers Squibb had a negative net margin of 0.11% and a positive return on equity of 27.48%. The business’s revenue was up 2.7% compared to the same quarter last year. During the same quarter in the prior year, the firm earned $1.72 EPS. Research analysts expect that Bristol-Myers Squibb will post 6.35 earnings per share for the current fiscal year.

The business also recently disclosed a quarterly dividend, which was paid on Monday, May 3rd. Stockholders of record on Thursday, April 1st were paid a $0.49 dividend. The ex-dividend date of this dividend was Wednesday, March 31st. This represents a $1.96 annualized dividend and a dividend yield of 3.07%. Bristol-Myers Squibb’s dividend payout ratio is currently 41.79%.

A number of research firms have recently weighed in on BMY. Zacks Investment Research upgraded shares of Bristol-Myers Squibb from a “hold” rating to a “buy” rating and set a $66.00 price target on the stock in a research note on Tuesday, April 6th. Morgan Stanley downgraded shares of Bristol-Myers Squibb from an “overweight” rating to an “equal weight” rating and reduced their price target for the company from $70.00 to $62.00 in a research note on Friday. TheStreet upgraded shares of Bristol-Myers Squibb from a “c” rating to a “b” rating in a research note on Thursday, April 29th. Truist upgraded shares of Bristol-Myers Squibb from a “hold” rating to a “buy” rating in a research note on Tuesday, April 13th. Finally, Truist Securities upgraded shares of Bristol-Myers Squibb from a “hold” rating to a “buy” rating and raised their price target for the company from $66.00 to $74.00 in a research note on Monday, April 19th. Three investment analysts have rated the stock with a hold rating, thirteen have assigned a buy rating and one has issued a strong buy rating to the company. The stock currently has a consensus rating of “Buy” and an average price target of $73.81.

In related news, CEO Giovanni Caforio sold 25,000 shares of Bristol-Myers Squibb stock in a transaction on Monday, March 22nd. The shares were sold at an average price of $62.20, for a total value of $1,555,000.00. Following the completion of the sale, the chief executive officer now owns 528,980 shares of the company’s stock, valued at approximately $32,902,556. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Insiders own 0.14% of the company’s stock.

Bristol-Myers Squibb Profile

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, and markets biopharmaceutical products worldwide. The company offers products in hematology, oncology, cardiovascular, and immunology therapeutic classes. Its products include Revlimid, an oral immunomodulatory drug for the treatment of multiple myeloma; Opdivo for anti-cancer indications; Eliquis, an oral inhibitor indicated for the reduction in risk of stroke/systemic embolism in NVAF, and for the treatment of DVT/PE; and Orencia for adult patients with active RA and psoriatic arthritis, as well as reducing signs and symptoms in pediatric patients with active polyarticular juvenile idiopathic arthritis.

Read More: What are some reasons analysts would give stocks a buy rating?

Institutional Ownership by Quarter for Bristol-Myers Squibb (NYSE:BMY)

Receive News & Ratings for Bristol-Myers Squibb Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bristol-Myers Squibb and related companies with MarketBeat.com's FREE daily email newsletter.